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Abstract
Central hypothyrodism (CeH) is a hypothyroid state caused by an insufficient stimulation by 
thyrotropin (TSH) of an otherwise normal thyroid gland. Several advancements, including 
the recent publication of expert guidelines for CeH diagnosis and management, have been 
made in recent years thus increasing the clinical awareness on this condition. Here, we 
reviewed the recent advancements and give expert opinions on critical issues. Indeed, CeH 
can be the consequence of various disorders affecting either the pituitary gland or the 
hypothalamus. Recent data enlarged the list of candidate genes for heritable CeH and a 
genetic origin may be the underlying cause for CeH discovered in pediatric or even adult 
patients without apparent pituitary lesions. This raises the doubt that the frequency of 
CeH may be underestimated. CeH is most frequently diagnosed as a consequence of the 
biochemical assessments in patients with hypothalamic/pituitary lesions. In contrast with 
primary hypothyroidism, low FT4 with low/normal TSH levels are the biochemical hallmark 
of CeH, and adequate thyroid hormone replacement leads to the suppression of residual 
TSH secretion. Thus, CeH often represents a clinical challenge because physicians cannot rely 
on the use of the ‘reflex TSH strategy’ for screening or therapy monitoring. Nevertheless, in 
contrast with general assumption, the finding of normal TSH levels may indicate thyroxine 
under-replacement in CeH patients. The clinical management of CeH is further complicated 
by the combination with multiple pituitary deficiencies, as the introduction of sex steroids or 
GH replacements may uncover latent forms of CeH or increase the thyroxine requirements.
Introduction
Central hypothyroidism (CeH) is a rare and heterogenous 
hypothyroid condition resulting from an insufficient 
stimulation of an otherwise normal thyroid gland by the 
hypophyseal thyrotropin hormone (TSH). This loss of 
central thyroid stimulation can result from a functional or 
an anatomical disorder of the hypothalamus and/or the 
pituitary, causing variable TSH secretion modifications (1, 2).
Epidemiology
CeH most frequently occurs as a sporadic form of 
hypothyroidism and can affect patients of all ages. There 
is no evidence of male gender prevalence despite the 
recent finding of X-linked forms (3). CeH incidence was 
estimated to range from 1:16,000 to about 1:100,000 in 
different adult or neonatal populations hypothyroid 
patients (4, 5, 6, 7, 8). This variability in the CeH 
prevalence seems to be dependent upon several factors, 
such as the ethnicity and the differences in diagnostic 
strategy sensitivity. Indeed, the diagnostic strategy 
used by the Dutch national health system, based on 
the combined evaluation of total T4 (TT4), thyroxine-
binding globulin and TSH (6), has proven to be more 
sensitive and to uncover milder forms of neonatal CeH 
that are not detected by the diagnostic strategy used in 
Japan and USA, based on the combination of low TT4 and 
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normal/low TSH (5, 7). Despite the possible association 
with life-threatening adrenal crisis in congenital multiple 
pituitary hormone defeciencies (MPHDs), CeH is not 
a direct cause of death. The addition of acquired forms 
of CeH on top of the incidence reported among Dutch 
newborns raises the suspicion that the prevalence of CeH 
in the general population is underestimated.
Pathogenesis
The pathogenic mechanisms underlying CeH are still 
undetermined in several cases although they variably 
involve both hypothalamic and pituitary cells. CeH can be 
either congenital or acquired. Congenital CeH is usually 
manifest in infancy, but has sometimes a delayed onset 
during childhood or adulthood. Genes causative for CeH 
can be divided into those leading to isolated form or to 
combined forms with an MPHD and are listed in Table 1. 
Nevertheless, more recently, other genes and syndromes 
have been variably associated with thyrotropin defects 
(see also Table 1).
On the other hand, the acquired forms of CeH are 
mainly related to expansive lesions of the hypothalamic/
pituitary region, although head trauma, vascular accidents, 
autoimmunity, hemochromatosis or iron overload and 
several iatrogenic causes are also accountable for several 
CeH cases. Acquired CeH is definitely more common in the 
adulthood and is prevalently caused by macroadenomas of 
the pituitary and their treatments. Craniopharyngiomas 
represent the most prevalent expansive lesion associated 
with CeH in pediatric patients. The causes of acquired 
CeH are listed in Table 2 (see also comments in Fig. 1).
Altogether these pathological mechanisms can lead to 
CeH through variable mechanisms:
a. impaired thyrotrope stimulation by the hypothalamic 
factors or modifications in the thyroid hormone 
feedback set-point (e.g. TRH resistance or IGSF1 or 
TBL1X or IRS4 mutations or hypothalamic lesions) 
(9, 10, 11, 12);
b. reduced pituitary TSH reserve (e.g. TSHβ mutations 
or a deficient number of thyrotrope cells or pituitary 
lesions causing the loss of the thyrotrope population);
c. impaired intrinsic bioactivity of the secreted TSH 
molecules (13, 14, 15, 16, 17).
The three mechanisms are frequently coexisting as a 
consequence of the expansive lesions of the sella region 
(16, 17). The impaired bioactivity of circulating TSH has 
been prevalently demonstrated by in vitro bioassays (15), 
but this phenomenon can also be supported in vivo by 
the impaired increment of circulating free T4 and/or T3 
following the TSH response upon TRH stimulation test 
(18, 19).
Clinical presentation
CeH represents a challenging condition in clinical 
practice as it is characterized by suboptimal accuracy 
of clinical and biochemical parameters for diagnosis 
and management. Clinical presentation of CeH may 
vary depending on the cause. It is worth noting 
that the typical manifestations of severe congenital 
hypothyroidism are rarely present at birth in most of the 
CeH patients since the chorionic gonadotropin could 
be effective in stimulating the fetal thyroid, differently 
from a primary thyroid defect, and thyrotrope function 
is not completely defective in particular when the 
hypothalamic stimulation is principally affected. Mental 
retardation can be particularly severe in case of delay in 
the diagnosis of isolated congenital CeH associated with 
biallelic TSHβ mutations, due to the false-negative results 
of the neonatal TSH screening for primary thyroid defects 
(3, 20, 21, 22, 23, 24, 25). However, when CeH diagnosis is 
reached in newborns, treatment should be given as soon 
as possible (Fig. 1).
Genetic CeH can more frequently be part of an MPHD 
and can be associated with growth retardation, delayed 
pubertal development and/or variable neurological defects 
that can be a direct effect of the genetic lesion (Table 1) (1, 
26, 27, 28, 29). IGSF1 followed by PROP1 are the genes 
most frequently accounting for the inheritable forms 
of CeH. However, a progressive onset of the thyrotrope 
defect beyond the critical neonatal period can be not 
infrequently seen in several of these genetic CeH cases 
(3, 9, 28, 30). On the other hand, some peculiar clinical 
stigmata illustrated in Table  1 can suggest specific gene 
defects such as the macrorchidism for IGSF1 or hearing 
defects for TBL1X (10, 11, 31, 32).
Acquired forms of CeH are usually sporadic and 
in most cases due to large pituitary macroadenomas 
with a suprasellar extensions, craniopharyngiomas 
and suprasellar tumors, head trauma, vascular accident 
or cranial irradiation (1, 28, 33). In these cases, the 
tumor size might cause either a defective functionality 
of the neurohypophysis with an associated diabetes 
insipidus and/or a compression of the optic chiasm with 
a direct consequence in the quality of the visual field. 
Moreover, these lesions usually affect both pituitary 
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and hypothalamus function with a resulting MPHDs 
clinical picture and hyperprolactinemia secondary to the 
pituitary stalk resection or compression. Thus, signs and 
symptoms due to this MHPD condition, such as menstrual 
disorders, decreased libido, hair loss, galactorrhea, 
pallor, altered lipid metabolism, visual defect, 
headache and others might overlap and cover the 
specific manifestations due to the hypothyroidism. 
All these manifestations can severely compromise the 
performance and wellbeing of the patients and generate 
negative effects on various tissues. Therefore, evaluation 
for CeH should always be included among the hormone 
Table 1 Candidate genes for inherited CeH forms and related phenotypes.
Gene OMIM Inheritance Phenotype
Isolated CeH
 TSHβ 188540 AR Neonatal onset with low TSH, high aGSU and normal PRL circulating levels, 
pituitary hyperplasia reversible on L-T4
 TRHR 188545 AR Normal TSH and low PRL circulating levels, blunted TSH/PRL responses to TRH, 
male index cases with growth retardation and overweight during childhood; one 
female proband with prolonged neonatal jaundice
 TBL1X 300196 X-linked Mild isolated CeH in males with normal TSH circulating levels and normal 
response to TRH stimulation test (only 1 out of 11 female carriers have CeH); 
hearing defects
 IRS4 300904 X-linked Mild isolated CeH in males with normal TSH circulating levels, blunted TSH 
response to TRH
Multiple pituitary hormone deficiencies
 IGSF1 300137 X-linked Mild CeH with normal TSH circulating levels and blunted response to TRH 
stimulation; males are preferentially affected but low FT4 can be found also in a 
minority of the female carriers, likely due to skewed X-chromosome inactivation; 
associated with low PRL levels, variable GH deficiency, transient mild 
hypocortisolism and metabolic syndrome; late adrenarche and delayed rise of 
testosterone in males, dissociated from testicular growth ending in post-
pubertal macrorchidism
 PUO1F1 173110 AR, AD Variable age of onset, associated with GH and PRL deficiency, prominent 
forehead, midface hypoplasia, depressed nose
 PROP1 601538 AR Variable age of onset, combined with GH, PRL LH/FSH deficiencies and delayed 
ACTH defects, small to large pituitary volume
 HESX1 601802 AR, AD Hypopituitarism associated with septo-optic dysplasia
 SOX3 313430 X-linked Anterior pituitary hypoplasia with ectopic posterior pituitary, persistent cranio-
pharyngeal canal and learning difficulties
 OTX2 600037 AD Anterior pituitary hypoplasia with ectopic posterior pituitary and ocular defects 
(ano-/micro-ophthalmia/retinal dystrophy)
 LHX3 600577 AR Hypopituitarism with inconstant ACTH defect, small to large pituitary, short and 
rigid cervical spine and variable hearing defect
 LHX4 602146 AR, AD Variable hypopituitarism, anterior pituitary hypoplasia with ectopic posterior 
pituitary, Arnold–Chiari syndrome, hypoplasia of the corpus callosum
 LEPR 601007 AR CeH with hyperphagia, obesity and combined with central hypogonadism
Genetic defects inconstantly associated with CeH
 SOX2 184429 AD Variable hypopituitarism, pituitary hypoplasia, microphthalmia, variable learning 
difficulties
 NFKB2 164012 AD Deficient anterior pituitary with variable immune deficiency (DAVID) syndrome 
associated with ACTH deficiency and variable GH and TSH defects
 CHD7 608892 AD CHARGE syndrome (Coloboma, Heart anomaly, choanal Atresia, Retardation, 
Genital and Ear anomalies) with ectopic posterior pituitary and variable LH/FSH, 
TSH and GH defects
 FGFR1 136350 AD Kallmann’s syndrome (KS) and normosmic congenital hypogonadotropic 
hypogonadism (nCHH), variable association with defects of other pituitary 
hormones including TSH, septo-optic dysplasia and ectopic posterior pituitary
 FGF8 600483 AR KS and nCHH, variable associations with defects of other pituitary hormones 
including TSH, holoprosencephaly and corpus callosum agenesia
 FOXA2 600288 AD Hypopituitarism with craniofacial and endoderm-derived organ abnormalities 
and hyperinsulinism
 PROKR2 607123 AR, AD Variable hypopituitarism associated with septo-optic dysplasia or pituitary stalk 
interruption syndrome
AD, autosomal dominant; AR, autosomal recessive; OMIM, online mendelian inheritance in men (https://www.ncbi.nlm.nih.gov/omim/).
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determinations of the patients with diseases of the 
hypothalamic–pituitary region (34).
Diagnosis
The diagnosis of CeH can be reached by three different 
means:
a. clinical manifestations (hypothyroid symptoms) – this 
is a rare event; a typical example is the poor growth 
associated with jaundice and muscle hypotonia in 
infants with congenital CeH;
b. biochemical findings (low, or even low–normal, free 
T4 with inappropriately low/normal TSH) – this is 
the most frequent case possibly occurring at birth 
because of a positive neonatal screening or during the 
biochemical workup of patients with known lesions 
of the hypothalamic–pituitary region or during their 
follow-up;
Table 2 Causes of acquired CeH forms.
Invasive and/or 
compressive lesion of the 
sella turcica region
Pituitary macroadenomas
Craniopharyngiomas
Meningiomas and gliomas
Rathke cleft cysts
Metastatic seeding
Carotid aneurysm
Iatrogenic causes Cranial surgery or irradiation
Drugs (e.g., rexinoids or mitotane)
Injuries Head trauma
Traumatic delivery
Vascular accidents Pituitary infarction
Sheenan syndrome
Subarachnoid hemorrhage
Autoimmune disease Lymphocytic hypophysitis 
(including the forms induced in 
post-partum or during therapy 
with check-point inhibitors)
Infiltrative lesions Iron overload
Sarcoidosis
Histiocytosis X
Infective diseases Tuberculosis
Mycoses
Syphilis
Figure 1
Flowchart for the diagnosis of CeH. CeH, central hypothyroidism; COS, controlled ovarian stimulation; ES, empty sella; IO, iron overload or 
hemochromatosis; MPHD, multiple pituitary hormone defect; MRI, magnetic resonance imaging; PID, pituitary infiltrative disease; PSI, pituitary stalk 
interruption; rhGH, recombinant human growth hormone; TBI, traumatic brain injury; VA, vascular accident.
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c. genetic investigations following one proband diagnosis 
– several patients diagnosed with isolated mild CeH 
in adulthood do not have the perception of being 
hypothyroid and only the treatment experience can 
uncover the beneficial effects of thyroid replacement 
on their wellbeing. The experience with CeH patients 
diagnosed by genetic testing tells us that gene 
defects can be a likely cause for mild idiopathic CeH 
discovered during adolescence or adulthood following 
an incidental biochemical finding of low free T4 (FT4).
However, diagnostic and clinical management of CeH is 
still nowadays a challenging condition due to the lack 
of accurate clinical and biochemical parameters. Very 
recently, a group of pediatric and adult endocrinologists 
have produced the 2018 Guidelines European Thyroid 
Association on the diagnosis and management of 
CeH (35). In their recommendations, experts agreed 
that diagnosis of overt CeH should be considered in 
every subject with low serum concentrations of FT4, 
measured by reliable immunoassay and low or normal 
immunoreactive TSH concentration, confirmed on two 
independent determination (35). A schematic illustration 
of the diagnostic workup for CeH based on the ETA 
guidelines is reported in Fig. 1.
Indeed, evidences in a series of CeH patients clearly 
established that diagnosis of this condition cannot 
be achieved by the single measurement of TSH. In this 
respect, the missed diagnosis of CeH represents the most 
important false-negative result of the ‘reflex TSH’ strategy 
that is frequently applied for the screening of thyroid 
function either in newborns or in adults (1, 36). Therefore, 
the FT4 determination, more than the TT4, which is 
influenced by the serum-binding protein variation (37, 
38) or the FT3, which might be low in some nonthyroidal 
illness or deiodinase defect rather than in CeH, represents 
the parameter with the highest diagnostic sensitivity and 
specificity in this hormone defect (1, 39, 40, 41, 42). As 
an additional complication, one should remember that 
slight elevations of serum TSH concentrations can also 
be found in some CeH patients with a predominant 
hypothalamic defect. In this subgroup of patients, TSH 
levels are superimposable to those generally found in 
subclinical or mild primary hypothyroidism, although 
the molecule is devoid of full biological activity and the 
FT4 is already in the hypothyroid range (13, 14, 16, 17). 
Conditions that can lead to low/normal TSH and low 
FT4 levels listed in Table 3 should also be ruled out in a 
correct differential diagnosis. Moreover, the presence of a 
possible interference in FT4 or TSH measurement should 
also be considered and excluded (1, 37, 38). Indeed, 
the FT4 absolute value is related to the assay applied. 
Although the equilibrium dialysis is the most accurate 
method for the determination of the FT4 levels, this is 
not compatible with the routine lab work out, and the 
automated FT4 assays are commonly used (38). Among 
these immunoassays, the so-called ‘one-step’ assays are 
surely less reliable then the ‘two-step’ methods. In these 
latter methods, an immunoextraction (back-titration) 
allows the removal of the interfering factors of the serum 
(e.g., T4/T3-binding auto-antibodies or abnormal-binding 
proteins). In case of a suspected FT4 assay interference, 
a ‘two-step’ method or a mass spectrometry should be 
considered to solve the question. Heterophile antibodies, 
such as anti-animal antibodies, which might be present 
in the patient sera, can interfere TSH measurements by 
immunometric assays, when they are directed against 
the same species as the assay antibodies. In particular, 
a heterophile antibody able to block the TSH binding 
to either capture or detection antibodies will lead to a 
negative immunoassay interference and a falsely low TSH 
level determination. This might cause the misdiagnosis of 
a primary hypothyroidism as a CeH. Due to the frequency 
of heterophile antibodies, most of the commercial TSH 
assays contain the pre-immune serum from the source 
animal in the reagents. Another cause of interference 
may be represented by the ‘macro-TSH’, which may 
lead to falsely elevated TSH concentrations. In this case, 
CeH patients might be interpreted as being affected by 
primary hypothyroidism. In the real life, a good advise 
to render less likely a suspected interference is the use of 
Table 3 Conditions associated with low/normal TSH and/or 
low, or even low–normal, free FT4 levels that could lead to 
erroneous CeH diagnosis or to transient CeH.
Severe form of nonthyroidal illness or sick euthyroid 
syndrome
Drugs inhibiting TSH secretion: (a) glucocorticoids; (b) 
dopamine; (c) cocaine; (d) anti-epileptics; (e) anti-psychotics; 
(f) metformin
Thyrotoxicosis-related conditions: Levothyroxine withdrawal 
syndrome, prolonged TSH suppression after recovery from 
thyrotoxicosis
Pregnancy related conditions: (a) Isolated maternal 
hypothyroxinemia (to be interpreted in the context of 
trimester-specific FT4 reference ranges for pregnant 
women). (b) Premature birth (delayed TSH rise in 
hypothyroid infants)
Genetic conditions: (a) Allen–Herndon–Dudley syndrome 
(MCT8 gene pathogenic allelic variants); (b) RTHα due to 
THRA heterozygous mutations; (c) TSHβ allelic variants with 
conserved bioactivity but lost immunoreactivity of 
circulating TSH
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alternative immunoassays including different antibody 
pairs or the measurement of TSH levels after removal of 
the interfering immunoglobulins by treating the serum 
with polyethylene glycol or protein G or by dilution and 
recovery test (1, 38).
Beyond interference, the conditions that can give 
rise to biochemical results similar to those found in CeH 
include different groups of conditions listed in Table  3 
(see also Fig.  1). In a hospital setting or in the elderly 
the non-thyroidal illnesses or euthyroid sick syndrome 
are the most frequent possibility and they are obviously 
hallmarked by a prevalent and often isolated fall of T3 or 
free T3 (FT3) levels and by the concomitance of severe or 
chronic disease states.
Treatments with drugs able to inhibit the TSH 
secretion or the recovery from a thyrotoxic state can 
sometimes be confused with a CeH. A careful collection 
of the personal history, the repetition of the biochemical 
examination and exclusion of an underlying primary 
thyroid disease are key to uncover such possibilities. 
Gestational hypothyroxinemia can come into differential 
diagnosis with CeH, but this risk may be greatly reduced 
by the definition of trimester-specific FT4 reference 
levels. The delayed TSH rise in premature babies can be 
associated with a transient CeH that is generally of short 
duration and does not require treatment in most cases. 
Furthermore, patients with rare inheritable defects of 
thyroid hormone action can have low FT4 and normal 
or slightly elevated TSH. However, patients affected with 
MCT8 or THRA mutations leading to Allan–Herndon–
Dudley syndrome or resistance to thyroid hormone α 
(RTHα) have distinct and typical clinical features and 
T3 levels at the upper limit of normal range (43). A 
peculiar confounding condition may be represented by 
TSHβ allelic variants with conserved bioactivity but lost 
immunoreactivity of circulating TSH (44). This condition 
should be suspected when undetectable or low TSH is 
repeatedly associated with clearly normal and stable 
thyroid hormone levels and confirmed by an absent TSH 
rise after TRH stimulation.
In familial, congenital or syndromic CeH cases, 
genetic analyses should be accomplished (35). The 
discovery of pathogenic variant(s) in one candidate gene 
can lead to uncover possible carriers and early diagnosis 
in the affected families and support the CeH diagnosis in 
uncertain cases, including those with a delayed evidence 
or onset of the biochemical abnormalities without an 
apparent cause. Genetic analysis can be done either 
with an automated direct sequencing of specific genes, 
following a phenotype-driven approach or by using a 
targeted next-generation sequencing technique and thus 
running in the same time a panel of multiple candidate 
genes (3, 35).
A still controversial issue is the diagnosis of the 
hidden or mild forms of CeH usually characterized 
by FT4 in the lower part of the normal range. Studies 
performed in patients with primary thyroid disease 
indicate that replacement therapy of mild or subclinical 
hypothyroidism may improve the wellbeing and physical 
or mental performances or prevent cardiovascular 
morbidities. The same should be true also for 
mild/hidden forms of CeH, but the lack of a sufficiently 
sensitive parameter hampers their recognition. 
In patients at risk, such as those on follow-up for 
hypothalamic/pituitary lesions or brain cancer survivors, 
or the carriers of pathogenic variants in novel candidate 
genes, the diagnosis of CeH can be supported by several 
investigations or findings (35).
These tests include:
 – abnormal TSH response to TRH stimulation (17, 45, 
46, 47, 48, 49, 50);
 – blunted nocturnal TSH rise (47);
 – impaired circulating TSH bioactivity (15, 16, 18, 51);
 – low TSH index (52);
 – progressive decrease of FT4 in patients on follow-up 
(>20% of the initial value) (1, 35, 41);
 – abnormal findings of parameters of thyroid hormone 
action (41, 42, 53).
The interpretation of these tests may be controversial 
and their application depends upon the resources and 
availability in the different clinical and laboratory settings 
(1, 35) (Fig. 1).
Therapeutical management
The first-line treatment of central hypothyroidism 
remains the replacement therapy using levothyroxine 
(L-T4) (35). Treatment is recommended in all patients 
receiving the diagnosis once a concomitant cortisol 
deficit has been excluded. In those presenting adrenal 
insufficiency or when its presence cannot be excluded, 
L-T4 supplementation should follow an adequate 
treatment with glucocorticoid in order to prevent the 
induction of an adrenal crisis. On the contrary, thyroid 
hormones enhance GH sensitivity and rise both IGF1 
levels and ALS, thus also increasing GH metabolic effect 
during therapies (54) and allowing a correct evaluation of 
the somatotrope function.
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In adult patients with central diseases, it is 
recommended to tailor the replacement L-T4 therapy 
according to the weight and the age of each patient (35). 
In patients older than 60 years of age and in those with 
cardiovascular comorbidities, the starting dose should 
be ranging 1.0–1.2 μg/kg/day. Furthermore, treatment 
of milder CeH forms (FT4 values within the lower limit 
of normal range) can be avoided in subjects older than 
75 years, as suggested by findings indicating a protective 
effect of mild or subclinical primary hypothyroidism 
on cardiovascular mortality risk in the elderly (55). 
Moreover, in elderly patients, as well as in those with 
long standing disease and higher cardiovascular risk, the 
ETA task force advised to start with lower doses of L-T4 
and then gradually uptitrate the dosage in subsequent 
weeks or months (35). It is important to evaluate the 
adequacy of the replacement after 6–8 weeks measuring 
FT4 and targeting this parameter above the median 
values of the reference range. During LT4 replacement, 
the concomitant determination of TSH is useless in CeH 
patients with low levels at diagnosis, whereas the lack of 
TSH secretion suppression in CeH patients with normal 
TSH concentrations at diagnosis may indicate under 
replacement. Indeed, all these considerations are valid 
only if the hormonal examinations are performed before 
or atleast 4 h after the daily intake of LT4 and are carried 
out in the same laboratory (1, 35).
Once the therapy has been judged adequate, it 
should be reevaluated annually measuring serum FT4. 
Measurement of TSH and T3 could be useful only to 
exclude the suspect of undertreatment and overtreatment, 
respectively. An insufficient replacement therapy should 
be suspected whenever FT4 concentrations are found 
below or at the lower limit of the normal range, especially 
when manifestations of hypothyroidism are present 
or TSH is still within the normal range. In contrast, an 
excessive LT4 intake should be considered whenever 
FT4 concentrations are above or at the upper limit 
of the normal range, in particular when clinical 
manifestations of thyrotoxicosis and/or high FT3 levels 
are present (1, 35).
Moreover, an adjustment in levothyroxine dosage 
may be required in many conditions (listed in Table 4) 
and FT4 and TSH should be reassessed 4–6 weeks after any 
change of the regimen.
Since the thyroid hormone levels are higher during 
childhood, higher doses of LT4 are required in children 
(56). In severe congenital CeH, it is mandatory to quickly 
reach adequate serum FT4 concentrations, and L-T4 
treatment should be initiated within 2 weeks from birth 
at the daily doses commonly used for primary congenital 
hypothyroidism (10–12 μg/kg/day) (35). In milder 
congenital forms, the starting doses of the replacement 
therapy could be lower (L-T4 5–10 μg/kg/day) to avoid 
an overtreatment and the same holds for diagnoses 
reached during childhood and adolescence (3.0–5.0 or 
2.0–2.4 μg/kg/day, respectively). Once the replacement 
therapy is started, pediatric patients should be monitored 
in order to maintain FT4 levels in the reference ranges 
for age, and their follow-up should be similar to what is 
done for primary hypothyroidism. In CeH children, LT4 
therapy was accompanied by an acceleration of growth 
velocity thus allowing the attainment of target height 
(9, 30, 47). A gradual downtitration is obviously required 
in transition to adulthood (57).
Finally, during pregnancy, it is recommended to 
increase the hormonal supplementation by 20–50% of 
the initial dose and to maintain the FT4 levels in the 
upper quartile of the reference range to compensate the 
expanding extracellular T4 pool and avoid hypothyroidism 
in the fetus (58).
Unlike the treatment of primary hypothyroidism, 
in which TSH is an excellent marker of an adequate 
replacement, the CeH management is more complex. Even 
low doses of L-T4 are able to suppress TSH secretion (42, 
59). In a comparison between patients with adequately 
treated primary thyroid disease and other patients 
presenting hypothalamic–pituitary lesions performed by 
Koulouri et al. in 2011, it was shown that FT4 levels were 
significantly lower in central hypothyroidism, suggesting 
a frequent undertreatment (39). Indeed, in acquired 
Table 4 Conditions requiring a reevaluation and possible 
adjustment of the replacement therapy.
Conditions at risk of an uptitration of L-T4 therapy
 Delay in psychomotor and cognitive development in infants 
and children
 Introduction of GH replacement therapy
 Introduction of estrogen replacement therapy or oral 
contraceptive 
 Pubertal development
 Controlled ovarian stimulation
 Pregnancy
 Weight gain
 Introduction of therapies affecting levothyroxine 
metabolism or absorption
Conditions at risk of a downtitration of L-T4 therapy
 Cardiovascular comorbidities
 Delivery
 Menopause
 Weight loss
 Discontinuation of GH or estrogen therapies or treatments 
affecting levothyroxine metabolism or absorption
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forms of CeH as those following surgery or radiotherapy 
for pituitary lesions or the start of treatments with 
an intrinsic risk of CeH, it could prove useful to assess 
FT4 concentrations before the intervention and LT4 
replacement could eventually be targeted to reach prior 
FT4 levels, but this is impossible in all the other forms 
of CeH.
The evaluation of biochemical indexes of thyroid 
hormone metabolism and action at the tissue level, such as 
SHBG, bone GLA protein for thyrotoxicosis or cholesterol 
for undertreatment, could sometimes be useful but are too 
frequently interfered by other hormonal alterations.
Importantly, in MPHDs other major confounders 
must be taken into account. Both estrogens and GH 
influence thyroid hormone transport and/or metabolism 
and consequently interfere CeH management (33, 60). 
Sex steroid and GH deficiencies can mask an underlying 
CeH while the introduction of these replacement 
therapies often requires an uptitration of L-T4; particular 
attention should also be given to the ovarian stimulation 
for assisted reproduction procedures because of the 
associated estrogen rise (61). Controversial is instead 
the potential influence of glucocorticoid replacement 
in uncovering a hidden CeH (62). According to these 
evidences, particular attention should be given to patients 
with MPHDs whenever new replacement therapies are 
added or modified.
Other treatments potentially leading to CeH include 
mitotane, which decreases viability of thyrotrope cells, 
and the rexinoids (e.g. bexarotene), directly repressing 
TSHβ expression, as well as novel biological drugs 
inducing hypophysitis such as ipilimumab or other check-
point inhibitors (63). Therefore, TSH and FT4 should be 
checked before and repeatedly during these treatments. 
At variance, dopamine agonists and somatostatin analogs 
exert milder and transient inhibition on thyrotropes.
Interestingly, a prospective study (64), performed on a 
small number of patients, uncovered a negative metabolic 
effect of an insufficient treatment of CeH, by evaluating 
lipid profile and the body fat mass by DEXA scan. These 
data, besides supporting the necessity of an adequate 
therapy maintaining FT4 values in the upper range of 
normality, suggest a negative effect even in the hidden 
forms of CeH, often undiagnosed.
Whenever there is an insufficient increment of serum 
FT4 or its decrement during treatment with a given dose 
of L-T4, malabsorption should be suspected (65).
As for the use of a combined therapy with L-T4 and 
L-T3 in CeH, it raises the same issues discussed for primary 
disease. In fact, there is no evidence from the many studies 
performed both in adults and in children to support a 
superiority of this treatment over the sole levothyroxine 
(66, 67, 68). However, it has been demonstrated in 
the Watts study that patients having a particular 
polymorphism in DIO2, Thr92Ala, the combined L-T4 and 
L-T3 therapy leads to a more favorable clinical outcome 
(69). This suggests that the subjects presenting particular 
SNPs in genes important for the peripheral regulation 
of hormones activity (such as deiodinases and thyroid 
hormone transporters) could benefit from the combined 
therapy with triiodothyronine according to their genetic 
background (70). Actually, the above mentioned studies, 
which failed to find any difference between the two 
approaches, could lack the power to underline such 
changes, since the DIO2 polymorphism is relatively 
infrequent (71). In particular, the combined therapy 
should be considered in patients lamenting symptoms 
despite an adequate supplementation with L-T4 alone, 
following the ETA guidelines (67). However, the lack of a 
highly reliable parameter to check overtreatment as TSH 
in primary disease, the combined L-T4/L-T3 replacement 
may be at a higher risk of thyrotoxicosis in CeH (68).
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